Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513997-23-00

Enrollment

Registered

2024-07-30

Start date

2017-10-16

Completion date

2025-10-14

Last updated

2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients with brain metastasis

Brief summary

The tumor targeting potential in brain metastasis will be visually scored as positive or negative by an experienced nuclear medicine physician, unaware of the HER2-status, The tumor targeting potential in brain metastasis will be assessed quantitatively using Standard Uptake Values (SUV) by an experienced nuclear medicine physician, unaware of the HER2-status.

Detailed description

If available, uptake will be evaluated during and after treatment and compared to baseline values. Results will be compared to information of patient's disease course.

Interventions

DRUG68Ga-NOTA-anti-HER2 VHH1

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The tumor targeting potential in brain metastasis will be visually scored as positive or negative by an experienced nuclear medicine physician, unaware of the HER2-status, The tumor targeting potential in brain metastasis will be assessed quantitatively using Standard Uptake Values (SUV) by an experienced nuclear medicine physician, unaware of the HER2-status.	—

Secondary

Measure	Time frame
If available, uptake will be evaluated during and after treatment and compared to baseline values. Results will be compared to information of patient's disease course.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026